$MLYS
Mineralys Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000193341423000087 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.026M $3.774M $3.039M
YoY Change 83.84% 24.19% 55.85%
% of Gross Profit
Research & Development $23.69M $22.50M $18.43M
YoY Change 202.95% 22.06% 90.18%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $27.71M $26.27M $21.47M
YoY Change 176.89% 22.37% 84.43%
Operating Profit -$26.27M -$7.423M
YoY Change 253.94%
Interest Expense $3.321M $3.513M $741.0K
YoY Change 255.19% 374.09% -208.33%
% of Operating Profit
Other Income/Expense, Net $1.000K $3.513M $4.000K
YoY Change 87725.0% 300.0%
Pretax Income -$24.39M -$22.76M -$20.73M
YoY Change 168.81% 9.81% 68.16%
Income Tax
% Of Pretax Income
Net Earnings -$24.39M -$22.76M -$20.73M
YoY Change 168.81% 9.81% 68.16%
Net Earnings / Revenue
Basic Earnings Per Share -$0.57 -$1.29
Diluted Earnings Per Share -$0.61 -$0.57 -$0.56
COMMON SHARES
Basic Shares Outstanding 41.11M shares 40.86M shares 5.181M shares
Diluted Shares Outstanding 39.93M shares 5.181M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $236.6M $253.8M $121.0M
YoY Change 114.85% 109.8%
Cash & Equivalents $49.30M $86.30M $48.96M
Short-Term Investments $187.3M $167.5M $72.00M
Other Short-Term Assets $12.54M $11.61M $933.0K
YoY Change 364.12% 1144.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $249.1M $265.4M $121.9M
YoY Change 120.81% 117.72%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.482M $12.13M
YoY Change
Other Assets $51.00K $51.00K $564.0K
YoY Change -96.87% -90.96%
Total Long-Term Assets $2.533M $12.18M $564.0K
YoY Change 55.3% 2059.57%
TOTAL ASSETS
Total Short-Term Assets $249.1M $265.4M $121.9M
Total Long-Term Assets $2.533M $12.18M $564.0K
Total Assets $251.6M $277.6M $122.5M
YoY Change 119.88% 126.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $601.0K $5.573M $2.563M
YoY Change -68.48% 117.44%
Accrued Expenses $9.881M $7.970M $3.812M
YoY Change 79.3% 109.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.48M $13.54M $7.220M
YoY Change 29.94% 87.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.48M $13.54M $7.220M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $10.48M $13.54M $7.220M
YoY Change 29.94% 87.58%
SHAREHOLDERS EQUITY
Retained Earnings -$124.7M -$100.3M
YoY Change 136.13%
Common Stock $4.000K $4.000K
YoY Change 300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $241.2M $264.0M $115.2M
YoY Change
Total Liabilities & Shareholders Equity $251.6M $277.6M $122.5M
YoY Change 119.88% 126.67%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$24.39M -$22.76M -$20.73M
YoY Change 168.81% 9.81% 68.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$28.98M -$19.03M -$19.04M
YoY Change 184.52% -0.02% 96.87%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$8.089M $4.007M -$71.76M
YoY Change -116.18% -105.58%
Cash From Investing Activities -$8.089M $4.007M -$71.76M
YoY Change -116.18% -105.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.6M
YoY Change 444.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 74.00K 184.0K 129.1M
YoY Change -106.93% -99.86% 442.11%
NET CHANGE
Cash From Operating Activities -28.98M -19.03M -19.04M
Cash From Investing Activities -8.089M 4.007M -71.76M
Cash From Financing Activities 74.00K 184.0K 129.1M
Net Change In Cash -37.00M -14.84M 38.29M
YoY Change -195.48% -138.75% 170.76%
FREE CASH FLOW
Cash From Operating Activities -$28.98M -$19.03M -$19.04M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1631000 usd
CY2023Q3 us-gaap Assets
Assets
277555000 usd
CY2022Q4 us-gaap Assets
Assets
114442000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5573000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1907000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6160000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13543000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8067000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
319000000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
364327000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
540000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52810000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
264012000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-52269000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
277555000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114442000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26273000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7423000 usd
us-gaap Operating Expenses
OperatingExpenses
56946000 usd
us-gaap Operating Expenses
OperatingExpenses
21471000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26273000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7423000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-56946000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3513000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
741000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
745000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9437000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
745000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22760000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6678000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47509000 usd
us-gaap Net Income Loss
NetIncomeLoss
-20726000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.36
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5181410 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5152752 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5152752 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-22925000 usd
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.926
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41105118 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41105118 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6419238 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6419238 shares
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100319000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22499000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6059000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46676000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18432000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3774000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1364000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10270000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3039000 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3513000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39930748 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39930748 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5181410 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34872287 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34872287 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-52269000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
158644000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
201359000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1276000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12141000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
285010000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1578000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22760000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
264012000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47509000 usd
us-gaap Net Income Loss
NetIncomeLoss
-20726000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4799000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
239000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3603000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
237000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
655000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8308000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
473000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5476000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2166000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19035000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
274883000 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
71759000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
122500000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-152383000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71759000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202990000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-561000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
184000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203174000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129087000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1401000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38293000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87701000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10662000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86300000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48955000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
159180000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
mlys Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction
DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
mlys Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction
DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
421000 usd
CY2023Q3 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
179600000 usd
CY2023Q3 us-gaap Investments And Cash
InvestmentsAndCash
265900000 usd
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
16.00
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100300000 usd
CY2023Q3 us-gaap Investments And Cash
InvestmentsAndCash
265900000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47500000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52200000 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
378800000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operatingsegment
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Estimates have been used in the following areas, among others: research and development accruals, fair value of the Company’s common stock prior to the closing of the Company’s IPO, and income taxes.
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q3 us-gaap Cash
Cash
1352000 usd
CY2022Q4 us-gaap Cash
Cash
2872000 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84948000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84829000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86300000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87701000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
50000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration of Credit Risk The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash balances in several accounts with two financial institutions which, from time to time, are in excess of federally insured limits.
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1600000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616151 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23186422 shares
CY2023Q3 mlys Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5853000 usd
CY2022Q4 mlys Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
4846000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current And Noncurrent
AccruedEmployeeBenefitsCurrentAndNoncurrent
1221000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current And Noncurrent
AccruedEmployeeBenefitsCurrentAndNoncurrent
665000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
896000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
649000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6160000 usd
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6166977 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
50000000 shares
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
16.00
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1578000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3603000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
237000 usd
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001933414-23-000087-index-headers.html Edgar Link pending
0001933414-23-000087-index.html Edgar Link pending
0001933414-23-000087.txt Edgar Link pending
0001933414-23-000087-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mlys-20230930.htm Edgar Link pending
mlys-20230930.xsd Edgar Link pending
mlys-3q2310qex311.htm Edgar Link pending
mlys-3q2310qex312.htm Edgar Link pending
mlys-3q2310qex321.htm Edgar Link pending
mlys-3q2310qex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mlys-20230930_cal.xml Edgar Link unprocessable
mlys-20230930_def.xml Edgar Link unprocessable
mlys-20230930_lab.xml Edgar Link unprocessable
mlys-20230930_pre.xml Edgar Link unprocessable
mlys-20230930_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending